Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study to Evaluate The Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.

Next Previous
Trial Profile

Phase II Study to Evaluate The Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Rilotumumab (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Dec 2015 Primary end point was changed from Radiological response rates (Time frame 6 months) to Radiographic Response (Time frame 2 years)
    • 09 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 Mar 2015 Planned End Date changed from 1 Feb 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top